NewAmsterdam Pharma (NAMS) Total Liabilities (2021 - 2026)

NewAmsterdam Pharma has disclosed Total Liabilities across 6 years of filings, most recently posting $67.4 million for Q1 2026.

• Total Liabilities for Q1 2026 came in at $67.4 million, up 64.24% year-over-year; the trailing twelve-month figure through Mar 2026 was $67.4 million (up 64.24% YoY), and the FY2025 annual result was $85.9 million, down 19.85% from the prior year.
• Total Liabilities came in at $67.4 million for Q1 2026 at NewAmsterdam Pharma, down from $85.9 million in the prior quarter.
• In the past five years, Total Liabilities ranged from a high of $512.5 million in Q2 2023 to a low of -$398.4 million in Q1 2023.
• The 5-year median for Total Liabilities is $59.0 million (2023), against an average of $34.4 million.
• Across the five-year window, Total Liabilities soared 320.1% in 2022 and slumped 88.44% in 2024, its largest moves.
• NewAmsterdam Pharma's Total Liabilities stood at $48.0 million in 2022, then advanced by 22.26% to $58.7 million in 2023, then soared by 82.47% to $107.1 million in 2024, then declined by 19.85% to $85.9 million in 2025, then retreated by 21.47% to $67.4 million in 2026.
• The last three Total Liabilities figures came in at $67.4 million (Q1 2026), $85.9 million (Q4 2025), and $58.4 million (Q3 2025), per Business Quant data.